Afinitor (Breast Cancer) - Analysis and Forecasts to 2020
NEW YORK, Nov. 23, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Afinitor (Breast Cancer) – Analysis and Forecasts to 2020
http://www.reportlinker.com/p0657207/Afinitor-Breast-Cancer-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Afinitor (Breast Cancer) – Analysis and Forecasts to 2020
Summary
GlobalData's pharmaceuticals report, "Afinitor (Breast Cancer) – Analysis and Forecasts to 2020" provides Afinitor sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Afinitor including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Afinitor including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2013-2020 for Afinitor in the seven major markets
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 4
2 Introduction 5
2.1 Breast Cancer Market 5
2.2 Epidemiology 5
2.3 Etiology and Risk Factors 7
2.3.1 Age and Gender 7
2.3.2 Genetic Inheritance 7
2.3.3 Harmonal Replacement Therapy 7
2.3.4 Radiation 7
2.3.5 Obesity 7
2.3.6 Alcohol Consumption 7
2.3.7 Late Child Birth 7
2.3.8 Use of Birth Control Pills 7
2.4 GlobalData Report Guidance 8
3 Breast Cancer: Market Characterization 9
3.1 Breast Cancer Market 9
3.2 Breast Cancer Market Forecasts and CAGR 9
3.3 Drivers of Breast Cancer Market 10
3.3.1 High Prevalence 10
3.3.2 Breast Cancer: Most Frequent Cancer in Women 10
3.3.3 Increasing Breast Cancer Incidence Rate 10
3.3.4 Decreasing Breast Cancer Mortality Rate 12
3.3.5 High Survival Rates of Breast Cancer 14
4 Staging of Breast Cancer: Introduction 15
4.1 Distribution of Patients by Stages 15
4.1.1 Stages 15
5 Predictive Biomarker in the Treatment of Breast Cancer 18
6 Treatment Options of Breast Cancer 20
6.1 Stage 0 Breast Cancer: Treatment Options 20
6.2 Early Stage Breast Cancer (Excluding Stage 0) 21
6.3 Metastatic Breast Cancer (MBC) 23
6.3.1 Endocrine Treatment: Adjuvant, First Line and Second Line 23
6.3.2 Cytotoxic Chemotherapy 25
6.3.3 Management of Patients with HER-2 Positive Patients 27
7 Afinitor 29
7.1 Introduction 29
7.2 Mechanism of Action 29
7.3 Clinical Studies 29
7.3.1 Phase III study to evaluate the efficacy and safety of Everolimus in Combination with Exemestane versus exemestane alone in post menopausal women with ER positive, HER2 negative metastatic breast cancer (BOLERO-2) 29
7.3.2 Phase I/II trial to determine the Safety and Efficacy of everolimus (E) plus trastuzumab (T) in Patients with T-resistant Metastatic Breast Cancer 30
7.3.3 Everolimus in Combination with trastuzumab and paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer (BOLERO-1) 30
7.3.4 Daily everolimus in Combination with trastuzumab and vinorelbine in HER2 Positive women with Locally Advanced or Metastatic Breast Cancer (BOLERO-3) 30
7.4 Approval Status of Afinitor 30
7.5 Factors Affecting Sales of Afinitor 30
7.5.1 Significant Efficacy in Combination with Hormonal Therapy 30
7.5.2 Increasing Use of Targeted Therapy 30
7.5.3 High Cost of Afinitor 31
7.5.4 Patent Expiry of Aromasin 31
7.6 Drug Risk Benefit Score 31
7.6.1 Relative Efficacy 31
7.6.2 Safety 31
7.6.3 Compliance 31
7.6.4 Dosing Convenience 32
7.7 Intensity of Competition 32
7.8 Sales Forecasts 32
7.8.1 Target Patient Pool of Afinitor 32
7.8.2 Dosing 33
7.8.3 Market Penetration 33
7.8.4 Annual Cost of Therapy 33
7.8.5 Sales Projections of Afinitor 34
8 Appendix 43
8.1 Market Definitions 43
8.2 Abbreviations 43
8.3 Research Methodology 43
8.3.1 Coverage 43
8.3.2 Secondary Research 44
8.3.3 Forecasting 44
8.3.4 Number of Patients Approved to take the Drug 44
8.3.5 Net Penetration of Drug 44
8.3.6 Net Annual Dosing 46
8.3.7 Annual Cost of Therapy 46
8.3.8 Primary Research 46
8.3.9 Expert Panels 46
8.4 Drug Sales Estimates Model 46
8.5 Contact Us 46
8.6 Disclaimer 47
8.7 Sources 47
List of Tables
Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5
Table 2: Five-Year Relative Survival Rates, By Stages 14
Table 3: Approval Status of Afinitor 30
Table 4: Drug Risk Benefit Score (DRB) Afinitor 31
Table 5: Estimated Annual Cost of Therapy of Afinitor, 2013 33
Table 6: Afinitor, Breast Cancer, Global, Sales Forecasts ($m), 2013–2020 34
Table 7: Afinitor, Breast Cancer, the US, Sales Forecasts ($m), 2013–2020 35
Table 8: Afinitor, Breast Cancer, the UK, Sales Forecasts ($m), 2013–2020 36
Table 9: Afinitor, Breast Cancer, France, Sales Forecasts ($m), 2013–2020 37
Table 10: Afinitor, Breast Cancer, Germany, Sales Forecasts ($m), 2013–2020 38
Table 11: Afinitor, Breast Cancer, Italy, Sales Forecasts ($m), 2013–2020 39
Table 12: Afinitor, Breast Cancer, Spain, Sales Forecasts ($m), 2013–2020 40
Table 13: Afinitor, Breast Cancer, Japan, Sales Forecasts ($m), 2013–2020 41
List of Figures
Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 2010–2020 9
Figure 3: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 11
Figure 5: Breast Cancer, Incidence, Worldwide, 2008-2030 11
Figure 6: All Cancers, Incidence, Worldwide, 2008-2030 12
Figure 7: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 8: Breast Cancer, Mortality, Worldwide, 2008-2030 13
Figure 9: All Cancers, Mortality, Worldwide, 2008-2030 13
Figure 10: Broad Classification of Breast Cancer, By Type 15
Figure 11: Classification of Non-Invasive Breast Cancer, By CIS 15
Figure 12: Classification of Invasive Breast Cancer, By Stages 16
Figure 13: Classification of Invasive Breast Cancer, By Treatment 16
Figure 14: Classification of Metastatic or Advanced Breast Cancer 17
Figure 15: Metastatic Breast Cancer Classification 17
Figure 16: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 18
Figure 17: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC 19
Figure 18: Breast Cancer Types in Decreasing Order of their Aggressiveness 19
Figure 19: Treatment Options, DCIS Breast Cancer 20
Figure 20: Treatment Options, LCIS Breast Cancer 21
Figure 21: Treatment Options, Stages I, II and IIIA 21
Figure 22: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 22
Figure 23: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 22
Figure 24: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 23
Figure 25: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 24
Figure 26: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 24
Figure 27: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 26
Figure 28: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 27
Figure 29: Drug Model Diagram of Afinitor in the US, EU and Japan 32
Figure 30: Afinitor, Breast Cancer, Global, Sales Forecasts ($m), 2013–2020 34
Figure 31: Afinitor, Breast Cancer, the US, Sales Forecasts ($m), 2013–2020 35
Figure 32: Afinitor, Breast Cancer, the UK, Sales Forecasts ($m), 2013–2020 36
Figure 33: Afinitor, Breast Cancer, France, Sales Forecasts ($m), 2013–2020 37
Figure 34: Afinitor, Breast Cancer, Germany, Sales Forecasts ($m), 2013–2020 38
Figure 35: Afinitor, Breast Cancer, Italy, Sales Forecasts ($m), 2013–2020 39
Figure 36: Afinitor, Breast Cancer, Spain, Sales Forecasts ($m), 2013–2020 40
Figure 37: Afinitor, Breast Cancer, Japan, Sales Forecasts ($m), 2013-2020 41
Figure 38: Afinitor, Breast Cancer, Global, Sales Distribution by Country ($m), 2019 42
Figure 39: Drug Model Diagram 45
Figure 40: Patients Approved to take the Drug 45
To order this report:
Pathology Industry: Afinitor (Breast Cancer) – Analysis and Forecasts to 2020
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article